CGON CG Oncology Therapeutics Forward Price-to-Revenue Multiple

Public company logo of CG Oncology, Inc. (CGON)

CG Oncology, Inc. (CGON) is scaling the expansion of its bladder cancer viral therapy in the US. The forward P/S indicator on GURU.Markets reflects this trend, where the value of 1225.50 expresses the metric level. The diversification of mono- and combination therapy programs reduces regulatory risks, yet the absence of stable cash flows leaves the company dependent on external financing until commercial launch.

CGON CG Oncology: Market Cap to Future Revenue Ratio in the range 11/14/2024 - 11/17/2026

Summary analytical data breakdowns for cgoncology.com (CGON)

- current price and projected stock value:
Initial company analysis:CGON (CG Oncology Corp)
Product sample of CG Oncology, Inc.

To objectively assess asset quality, use the ratio of current market capitalization to projected revenue, which measures the market value of each unit of future sales. By analyzing the forward price-to-sales valuation, an investor can determine if an asset is overbought, which is critical for CG Oncology, Inc. (CGON), as its commercial sector transitions into a stage of stable profit generation driven by high demand for innovative cancer therapy.

Who CG Oncology, Inc. competes with

Forward P/S Multiple ONC (BeiGene Oncology)|Forward P/S Multiple Halozyme Corp HALO|RVMD: Forward Price-to-Revenue Multiple|Ascentage Pharma Group (AAPG) - Forward Price-to-Revenue Multiple|URGN: Forward P/S Multiple|Bicara Therapeutics Inc (BCAX) - Forward P/S Multiple|Price-to-Projected Revenue Ratio personalis.com|Forward Price-to-Revenue Multiple Erasca Corp (ERAS)|Forward Price-to-Revenue Multiple DCTH (Delcath)|Market Cap to Expected Sales Ratio Y-mAbs Therapeutics, Inc.|Forward P/S Multiple AURA (Aura Biosciences Inc)|Forward Price to Sales CADL|ARAY: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue CTOR|Price-to-Projected Revenue Ratio TuHURA Biosciences Inc.|TARA: Forward Price to Sales|Price-to-Projected Revenue Ratio Fate Therapeutics (FATE)|Market Cap to Expected Sales Ratio Aadi Bioscience|Price-to-Projected Revenue Ratio TScan Therapeutics Inc TCRX|CSBR: Market Cap to Projected Revenue|XBIT: Forward Price-to-Revenue Multiple|Forward Price to Sales CVM (cel-sci.com)|OSTX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Forward P/S Multiple|Market Cap to Projected Revenue ANL (Adlai Nortye)|Price-to-Projected Revenue Ratio Veru Pharma (VERU)|Forward P/S Multiple Tempest Tx (TPST)|Price-to-Projected Revenue Ratio xiliotx.com XLO|Enochian BioSciences - Price-to-Projected Revenue Ratio|Mural Oncology - Forward P/S Multiple|KAPA - Forward P/S Multiple|OnKure Therapeutics Inc (OKUR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple CytoMed|Price-to-Projected Revenue Ratio curis.com|Forward Price-to-Revenue Multiple Apollomics, Inc. (APLM)|Forward P/S Multiple THAR|Advanced Biomed Corp - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Genprex GNPX|Market Cap to Expected Sales Ratio Calidi Bio (CLDI)|sunshinebiopharma.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio xeneticbio.com|salariuspharma.com (SLRX) - Price-to-Projected Revenue Ratio|Purple Biotech Ltd. - Forward Price to Sales|Price-to-Projected Revenue Ratio AON|Forward P/S Multiple BeiGene Ltd.|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|Forward Price-to-Revenue Multiple Elevation Oncology, Inc. ELEV|Forward P/S Multiple ICAD (iCAD Inc.)|IKNA - Forward Price-to-Revenue Multiple|NTBL: Forward Price-to-Revenue Multiple|viracta.com (VIRX) - Forward Price-to-Revenue Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Corp (NAYA) - Forward P/S Multiple|AAPGV (Ascentage) - Forward P/S Multiple